|
|
The NMP22® BladderChek® Test is the only in-office test approved by the FDA for the diagnosis of bladder cancer. The NMP22 BladderChek Test is a painless and non-invasive assay, performed on a single urine sample, that detects elevated levels of NMP22 protein.
|